Biophysics

Both biophysical characterization and interaction analysis play crucial roles in modern drug discovery, offering invaluable insights into the behavior and properties of diverse therapeutic modalities. Our biophysical assays are regularly incorporated into our integrated drug discovery projects, working in tandem with biochemical or cell-based assays to quickly return binding data to our ADMET/DMPK and medicinal chemistry colleagues.  

Modality-agnostic biophysical analysis 

Our biophysical sciences team uses state-of-the-art tools and a deep understanding of biophysical methodologies to investigate binding interactions, molecular stability and aggregation propensity, all of which are essential for evaluating drug-target relationships in a wide range of therapeutic entities including small molecules, oligonucleotides, TPDs (PROTACS and molecular glues), peptides, proteins, antibodies, and various viral- and non-viral vectors. 

The team not only offers precise data interpretation but also customized guidance on a biophysics cascade strategy and complementary approaches. Our industry-leading turnaround times ensures a rapid transition from early-stage discovery to candidate optimization, advancing our clients’ projects with unparalleled precision, efficiency, and scientific rigor. 

Comprehensive suite of biophysical technologies  

Our high-end biophysics platform accelerates every stage of drug discovery — from hit finding and confirmation to hit-to-lead and lead optimization. We generate full mechanistic, kinetic, thermodynamic, and structural profiles of novel compounds to guide confident decision-making.

We quickly identify the best biophysical techniques, taking into account factors such as parameters to be measured, sample type, throughput needs, material availability, and solubility of interacting partners. Our diverse technologies provide insights into a wide range of molecular interactions, including:

• Fragment–protein
• Small molecule–oligonucleotide
• Peptide–protein
• Protein–protein
• Antibody–antigen
• Nanobody interactions

‍

To ensure robust data quality, we use a suite of advanced characterization tools to validate protein reagents before screening and to support product development with precision and efficiency. Our technology stack includes:

• Dynamic or Electrophoretic Light Scattering (DLS/ELS)
• Differential Scanning Calorimetry (DSC)
• Size Exclusion Multi Angle Light Scattering (SEC-MALS)

‍

Leveraging experience across diverse therapeutic modalities — including proteins, monoclonal antibodies, vaccines, PEGylated proteins, antibody-drug conjugates, oligonucleotides, glycoproteins, and biosimilars — we apply advanced biophysical technologies to deliver detailed insights into your drug substance.

We can assess:

• Secondary and tertiary structure
• Aggregation and oligomerization
• Degradation pathways
• Formulation stability, including forced degradation and compatibility with various buffers and excipients

‍